Antonio Regalado

Antonio Regalado

Creator
0 followers

Biomedicine editor at MIT Technology Review; covers cutting-edge biotech breakthroughs and their societal impact.

FDA's Prasad Paradox: Conflicting Strictness on Bespoke Therapies
SocialJan 8, 2026

FDA's Prasad Paradox: Conflicting Strictness on Bespoke Therapies

Predictions for cell therapy and gene therapy in 2026. Most interesting is the "Prasad Paradox", meaning a general state of contradiction at the FDA biologics division around laxness and strictness, including misapplication of the concept of "bespoke" therapies.

By Antonio Regalado